AUTHORS
Ibrahim Muhsen, MD, Kwang Wooahn, PhD2, Tiening Chen, MS3, Jinalben Patel, MPH, BDS4, Cameron J. Turtle, MBBS, PhD5, Peter Riedell, MD6, Craig Sauter, MD7, Mazyar Shadman, MD, MPH8, Mehdi Hamadani, MD9, Alex Francisco Herrera, MD10, Christina Poh, MD11
AFFILIATIONS
1 The University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 The University of Sydney, Sydney, Australia
6 University of Chicago, Chicago, Illinois, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 University of Washington, Seattle, Washington, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 City of Hope, Durate, California, United States
11 City of Hope, Durate, California, United States
ABSTRACT
Introduction: Nodal T-follicular helper (TFH) cell lymphomas, encompassing angioimmunoblastic-type (AITL), follicular-type, and not otherwise specified (NOS) subtypes, are associated with poor outcomes with standard front-line anthracycline-based chemotherapy, with 5-year overall survival (OS) rates of approximately 30%. Consolidative autologous hematopoietic cell transplantation (auto-HCT) is commonly utilized in eligible patients achieving remission; however, whether auto-HCT outcomes differ by nodal TFH subtype has not been evaluated. We sought to compare outcomes following auto-HCT between AITL and non-AITL nodal TFH cell lymphomas.
Methods: Using the CIBMTR database, we identified adult patients (≥18 years) with nodal TFH cell lymphoma who underwent first auto-HCT from 2018 through June 2024. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS), cumulative incidence of relapse/progression and non-relapse mortality (NRM) as competing events, and hematopoietic recovery. Propensity score matching was performed to compare outcomes between AITL and non-AITL subtypes, adjusting for age, sex, race/ethnicity, HCT-CI, Karnofsky performance status (KPS), conditioning regimen, time from diagnosis to auto-HCT, number of prior therapies, disease status at time of auto-HCT, and year of auto-HCT. OS and PFS were estimated using the Kaplan-Meier method, and Cox proportional hazards regression was used to estimate hazard ratios.
Results: Of 829 patients identified, 470 were included after propensity score matching: 394 (84%) AITL and 76 (16%) non-AITL subtype (51 nodal TFH-NOS and 25 follicular-type). Median age was 62.8 years (range, 18.3–78.6). Males comprised 57% of patients in both cohorts. The majority underwent auto-HCT after first-line therapy (73% AITL vs 71% non-AITL), and most received BEAM or BEAM-like conditioning (84% AITL vs 78% non-AITL). Complete remission (CR) at time of auto-HCT was more frequent in AITL patients (79% vs 74%), while partial remission (PR) was more common in the non-AITL group (22% vs 18%). Median time from diagnosis to auto-HCT was 7.3 months (7.2 AITL vs 7.5 non-AITL). Median follow-up was 24.9 months (24.9 AITL vs 24.1 non-AITL). There was no significant difference in OS between groups (p=0.66), with 1-year OS of 83% in both groups and 3-year OS of 65% and 67% for AITL and non-AITL, respectively. PFS was also similar (p=0.59), with 1-year PFS of 58% and 61% and 3-year PFS of 40% and 41% for AITL and non-AITL, respectively. Cumulative incidence of relapse/progression was similar between groups (3-year: 52% vs 52%; p=0.36). Three-year NRM was 7% in both groups. Hematopoietic recovery was comparable, with 99% of patients in both groups achieving neutrophil engraftment by day 100. Histologic subtype was not associated with OS (HR 0.89, 95% CI 0.55–1.45; p=0.65) or PFS (HR 0.89, 95% CI 0.64–1.23; p=0.47). Factors independently associated with inferior OS included age ≥66 years (HR 3.39, 95% CI 1.06–10.86; p=0.040) and ≥3 prior lines of therapy (HR 1.90, 95% CI 1.10–3.29; p=0.022). KPS <90 (HR 1.37, 95% CI 1.08–1.74; p=0.011) and PR at time of auto-HCT (HR 1.55, 95% CI 1.12–2.14; p=0.008) were independently associated with inferior PFS.
Conclusion: In this large registry-based analysis of patients with nodal TFH cell lymphomas, outcomes following auto-HCT were comparable between AITL and non-AITL subtypes, with no significant differences in OS, PFS, NRM, or relapse/progression. Disease status at time of auto-HCT, KPS, age, and number of prior lines of therapy were identified as key determinants of outcome rather than histologic subtype. These findings suggest that histologic subtype should not influence the decision to pursue auto-HCT and highlight the need for novel approaches to reduce relapse rates in this population.
DISCLOSURES
Ibrahim Muhsen, MD: No relevant conflicts of interest to declare.